阿莫克拉联合微卡治疗耐多药肺结核的临床研究

Clinical research of amoksiklav combined with microcalorie in MDR-tuberculosis

目的观察以阿莫克拉联合微卡为主药的化疗方案治疗耐多药结核病的疗效及安全性。方法2002年10月～2007年1月住院耐HR的肺结核患者61例,随机分成治疗组和对照组观察痰菌阴转、空洞闭合、病灶吸收、症状改善情况及治疗期间的副作用。结果观察治疗12个月、症状改善87.5%明显多于对照组62.1%;痰菌阴转率治疗组为90.7%,对照组为72.3%病灶吸收率治疗组为84.4%,对照组为65.5%,空洞闭合率治疗组为75%,对照组为59.3%。结论阿莫克拉联合微卡治疗耐多药肺结核是有效、安全可靠,无毒副反应。

Objective To observe the curative effect and safety of amoksiklav combinedwith microcalorie in MDR-tuberculosis. Methods 61 patients with lungtuberculosis of HR-fast between October of 2002 to January of 2007 in hospital were divided into two groups （the therapy group and the contrast group）. The measures included bacterium in sputum changed-into-negative rate, cavitas closure ratio, focus of infection absorbed, symptom improvement and drug safety in the process of therapy. Results In the 12 months of study, the rate of symptoms in the therapy group was 87.5%, which was more than the contrast group obviously. The sputum changed-into-negative rate was 90. 7% in the therapy group and 72. 3% in the contrast group. Conclusion Amoksiklav combined with microcalorie in MDR-tuberculosis is effective, secure and has little side-effect.